Qitan Technology completed a $101 million Series C round to support its commercialized nanopore devices. Takeda was approved to launch Exkivity (mobocertinib) in China.
invoX Pharma, a Sino Biopharm subsidiary, will pay $161 million to acquire F-Star, a Cambridge, UK clinical-stage company developing bispecific drugs for immunotherapies.